Oxford StemTech provides a high‑throughput, non‑integrating iPSC reprogramming service called ReproPlex™ that can generate hundreds to thousands of pluripotent stem cell lines from PBMCs at low cost. The company also offers end‑to‑end quality control, custom differentiation pipelines, and access to a curated iPSC repository, enabling academic and industry researchers to accelerate disease modeling, drug screening, and precision‑medicine projects.
Funding
Funding not disclosed
Founders
Product
Problem
Researchers often need large numbers of high-quality induced pluripotent stem cells (iPSCs) for disease modeling, drug screening, and precision‑medicine projects, but conventional reprogramming methods are costly, low‑throughput, and may introduce genomic alterations that compromise data reliability.
Solution
Oxford StemTech offers a scalable, non‑integrating iPSC reprogramming service called ReproPlex™ that can generate hundreds to thousands of iPSC lines from peripheral blood mononuclear cells (PBMCs) with high efficiency and low per‑sample cost. The platform combines automated cell culture, optimized reprogramming factor delivery, and rigorous quality‑control pipelines to ensure pluripotency, genomic stability, and reproducibility across batches. Clients can also access downstream services such as directed differentiation into specific cell types, comprehensive phenotypic profiling, and a curated repository of pre‑characterized iPSC lines. By handling the entire workflow—from PBMC isolation to validated iPSC clones—Oxford StemTech enables researchers to accelerate experimental timelines and focus on downstream discovery rather than cell‑line generation.
Target Audience
Primary customers are academic laboratories, biotech companies, and pharmaceutical R&D teams that require large‑scale, high‑quality iPSC resources for disease modeling, target validation, and drug discovery.
Features
- ReproPlex™ high‑throughput reprogramming capable of processing hundreds of samples in parallel within months
- Non‑integrating reprogramming vectors that preserve genomic integrity and produce stable iPSC clones
- End‑to‑end quality‑control suite including pluripotency marker profiling, karyotype analysis, and functional assays
- Custom differentiation pipelines to generate disease‑relevant cell types on demand
- Access to an extensive iPSC repository with fully characterized lines for rapid project initiation
- Integrated PBMC isolation service delivering high‑purity starting material for reprogramming